Healthier Choices Management Corp. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Healthier Choices Management Corp. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $14.65M | Mar 27, 2019 |
| FY2018 | Dec 31, 2017 | $12.95M | Mar 27, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.0K | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $501 | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $617 | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | $29.27M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $13.32M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $13.92M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $15.11M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $14.65M | May 13, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $10.57M | Mar 27, 2017 |
| FY2016 | Dec 31, 2015 | $5.25M | Mar 27, 2017 |
| FY2015 | Dec 31, 2014 | $15.28M | Apr 8, 2016 |
| FY2014 | Dec 31, 2013 | $25.99M | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $21.35M | Feb 26, 2014 |
| FY2012 | Dec 31, 2011 | $15.98M | Mar 29, 2013 |
| FY2011 | Dec 31, 2010 | $10.92M | Mar 27, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($27.9K) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($66.3K) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($170) | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | $10.22M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $5.29M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $5.78M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $6.48M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $7.16M | May 13, 2020 |
| FY2018 | Dec 31, 2017 | $6.27M | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | $5.23M | Mar 15, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.02M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($11.89M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($18.48M) | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | ($7.22M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($4.04M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($3.72M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($2.80M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | ($13.16M) | May 13, 2020 |
| FY2018 | Dec 31, 2017 | ($9.87M) | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | $10.68M | Mar 15, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.03M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($8.50M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($7.45M) | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | ($8.65M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($4.74M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($3.45M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($4.41M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | ($2.98M) | May 13, 2020 |
| FY2018 | Dec 31, 2017 | ($10.29M) | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | ($8.86M) | Mar 15, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $312.0K | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | $174.0K | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $159.0K | Feb 26, 2014 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $32.22M | Mar 27, 2024 |
| FY2023 | Dec 31, 2022 | $18.88M | Mar 27, 2024 |
| FY2021 | Dec 31, 2021 | $10.03M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $8.84M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $10.42M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $9.95M | May 13, 2020 |
| FY2018 | Dec 31, 2017 | $16.44M | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | $9.70M | Mar 15, 2018 |
| FY2016 | Dec 31, 2015 | $9.37M | Mar 27, 2017 |
| FY2015 | Dec 31, 2014 | $11.13M | Apr 8, 2016 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.88M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($3.66M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($4.74M) | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | ($3.87M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($3.53M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($2.28M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($3.54M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | ($143.5K) | May 13, 2020 |
| FY2018 | Dec 31, 2017 | ($2.82M) | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | ($7.32M) | Mar 15, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $47.2K | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $184.3K | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | $480.9K | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $56.4K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $24.7K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $32.9K | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $75.3K | May 13, 2020 |
| FY2018 | Dec 31, 2017 | $142.9K | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | $25.3K | Mar 15, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.47M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $2.22M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $30.97M | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | $55.26M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $34.44M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $11.87M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $14.01M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $15.17M | May 13, 2020 |
| FY2018 | Dec 31, 2017 | $11.70M | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | $17.23M | Mar 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.59M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $2.67M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $23.10M | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | $20.33M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $5.21M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $9.62M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $8.10M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $6.75M | May 13, 2020 |
| FY2018 | Dec 31, 2017 | $11.26M | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | $14.78M | Mar 15, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.23M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($1.56M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2023 | $6.76M | Mar 27, 2026 |
| FY2024 | Dec 31, 2022 | $20.21M | Apr 14, 2025 |
| FY2023 | Dec 31, 2021 | $29.23M | Mar 27, 2024 |
| FY2022 | Dec 31, 2020 | $2.26M | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $5.90M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $8.43M | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | $444.3K | May 13, 2020 |
| FY2018 | Dec 31, 2016 | $2.51M | Mar 27, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2022 | $5.75M | Mar 27, 2024 |
| FY2023 | Dec 31, 2021 | $916.0K | Mar 27, 2024 |
| FY2022 | Dec 31, 2020 | $916.0K | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $956.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $1.44M | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | $481.3K | May 13, 2020 |
| FY2018 | Dec 31, 2016 | $481.3K | Mar 27, 2019 |
| FY2017 | Dec 31, 2015 | $3.18M | Mar 15, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($82.05M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($75.04M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($62.10M) | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | ($43.61M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($36.40M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($32.36M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($28.64M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | ($25.73M) | May 13, 2020 |
| FY2018 | Dec 31, 2017 | ($12.57M) | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | ($2.75M) | Mar 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.14M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.19M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $3.66M | Apr 14, 2025 |
| FY2021 | Dec 31, 2021 | $26.50M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $925.5K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.53M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $7.06M | May 13, 2020 |
| FY2018 | Dec 31, 2017 | $7.88M | Mar 27, 2019 |
| FY2018 | Dec 31, 2016 | $13.37M | Mar 27, 2019 |
| FY2017 | Dec 31, 2015 | $27.21M | Mar 15, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $3.56M | Mar 27, 2024 |
| FY2023 | Dec 31, 2022 | $2.91M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $3.4K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $4.92M | Mar 31, 2022 |
| FY2018 | Dec 31, 2018 | $1.40M | Mar 27, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 0 | Mar 27, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
| FY2014 | Dec 31, 2014 | 0 | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | 0 | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | 0 | Feb 26, 2014 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 0 | Mar 27, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
| FY2014 | Dec 31, 2014 | 0 | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | 0 | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | 0 | Feb 26, 2014 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 525.16B | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 481.27B | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | 478.27B | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | 339.74B | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | 339.74B | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 143.84B | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 67.70B | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | 66.62B | May 13, 2020 |
| FY2018 | Dec 31, 2017 | 29.35B | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | 14.21B | Mar 15, 2018 |